ACB:CA:CDX-Aurora Cannabis Inc.

EQUITY | Drug Manufacturers | TSX Venture Exchange

Last Closing

USD 12.78

Change

-0.25 (-1.92)%

Market Cap

USD 0.76B

Volume

0.01B

Analyst Target

USD 14.29
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Aurora Cannabis Inc is a medical marijuana company. The Company is engaged in producing and distributing medical marijuana pursuant to the Marijuana for Medical Purposes Regulations.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-03-21 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
LG:CA Lahontan Gold Corp.

N/A

USD 0.05B

ETFs Containing ACB:CA

CNDA Concord Acquisition II Co.. 0.00 % 0.70 %

-0.01 (-0.05%)

USD 0.23B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 88.50% 76% C+ 99% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 88.50% 76% C+ 99% N/A
Trailing 12 Months  
Capital Gain 26.79% 60% D- 95% A
Dividend Return N/A N/A N/A N/A F
Total Return 26.79% 60% D- 94% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain 179.08% 100% F 99% N/A
Dividend Return 179.08% 100% F 99% N/A
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 189.93% 10% F 1% F
Risk Adjusted Return 94.29% 100% F 88% B+
Market Capitalization 0.76B 94% A 98% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers) Ratio vs. Market (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1,278.00 6% 0%
Price/Book Ratio 2.90 65% 18%
Price / Cash Flow Ratio -11.72 53% 96%
Price/Free Cash Flow Ratio -22.42 82% 89%
Management Effectiveness  
Return on Equity -2.46% 76% 31%
Return on Invested Capital -7.41% 47% 14%
Return on Assets -2.14% 76% 29%
Debt to Equity Ratio 10.75% 64% 84%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.